Table 2.
Comparison of patients' adherencea to treatment during baseline and follow-up periods in the intervention and control groups.
| Type of agent | Intervention | Control | Unadjusted | Adjustedb | ||||
| BLc, n (%) |
F-Ud, n (%) |
BL, n (%) |
F-U, n (%) |
BL risk ratio (95% CI), P | F-U risk ratio (95% CI), P | BL risk ratio (95% CI), P | F-U risk ratio (95% CI), P | |
| Antihypertensive (nI e=561, nC f=1008) |
439 (78.3) | 447 (79.7) | 799 (79.27) | 759 (75.30) | 0.99 (0.94-1.04), .64 |
1.06 (1.00-1.12), .04 |
0.99 (0.94-1.05), .84 |
1.06 (1.00-1.12), .04 |
| Antihyperlipidemic (nI e=474, nC f=913) |
372 (78.5) | 368 (77.6) | 691 (75.7) | 706 (77.3) | 1.04 (0.98-1.10), .23 |
1.00 (0.95-1.07), .90 |
1.04 (0.98-1.10), .21 |
1.01 (0.95-1.07), .86 |
aAdherent is defined as patients with proportion of days covered (PDC) ≥.80 (percentage with PDC ≥80%).
bFor antihypertensive agents: adjusted for diabetes, body mass index (BMI), and primary care visits per year; for antihyperlipidemic agents: adjusted for diabetes and primary care visits per year.
cBaseline (BL).
dFollow-up (F-U).
eNumber of included patients in the intervention group (nI).
fNumber of included patients in the control group (nC).